Home Creators Posts Import Register Favorites Logout

Downloads

  • David Fajgenbaum Master Audio.mp3

Some files exceed the archive size limit and weren't saved: 1 file. Please note these limits are in place to keep this site running long term, without costing a fortune. You can favorite the creator though, certain milestones increase the limit.

Content

Dr. David Fajgenbaum, MD, MBA, MSc, is a pioneering physician-scientist, tenured professor at the Perelman School of Medicine at the University of Pennsylvania, and national bestselling author who transformed his personal battle with the rare, deadly Castleman disease into a global mission to accelerate cures for humanity's 12,000 known diseases.

Diagnosed after losing his mother to cancer, Fajgenbaum endured five near-death experiences before using his medical training to identify sirolimus—a repurposed drug—as a life-saving treatment, achieving remission, marking over a decade cancer-free as of 2025.

A Georgetown University graduate with advanced degrees from Oxford and Wharton, he co-founded the Castleman Disease Collaborative Network (CDCN) and Every Cure, leveraging AI and drug repurposing to unlock hidden treatments, earning spots on TIME's 2025 TIME100 Health list and major media recognition for his "cure thyself" story. Through his book Chasing My Cure and speaking engagements, Fajgenbaum inspires hope, advocates for patient-driven research, and pushes for policy changes to speed up cures for rare diseases affecting millions worldwide.

Files

Comments

Ksg Sherley

Going to enjoy this one. Dont believe afraid to ask difficult technical questions...even if you dont understand the answer. Its ok...we can look it up

B McDermott

My little brother had a brain tumor when he was 1. This was back in 1997. IDK what the experimental medicine was, but my mom said yes to it. He's now 29 years old. The tumor was inoperable, so he still has it but it's "dead". I'm terrified one day it'll come back.

Steve Mc

I’m a firm believer that we already have the meds and procedures to cure some of the most deadly diseases. But there’s little financial incentive for pharma to recombine old meds into treatments.